A clinician researching digital patient platforms can encounter several familiar names without realising that they sit within the same group. That matters when comparing suppliers, considering a move between countries or deciding how much of a practice to run through one commercial ecosystem. It does not mean that every brand offers the same product, contract or patient audience.
Docplanner is a useful example of this distinction. This article explains the relationship between Doctoralia, MioDottore and jameda using official information checked on 18 October 2026, then examines the practical questions that shared ownership creates. The strategic observations are an analysis of the model, not claims about confidential group plans or guaranteed future integration.
The brand names are local entry points
Docplanner's group website identifies MioDottore in Italy, jameda in Germany and Doctoralia-branded services in several markets, including Spain and Mexico. Other countries use different local names. The group presents patient discovery and booking alongside tools for clinicians and larger healthcare organisations.
The local name is therefore not merely a translation of a universal contract. A clinician should start with the country where the practice operates and the professional product available there. The relevant currency, patient expectations, support arrangements and legal documentation may differ.
Shared ownership provides useful commercial context, but it is not a substitute for reviewing the actual service. A favourable experience reported by a doctor in one market does not establish that another country's product will solve the same problem.
What the local professional offers illustrate
The jameda professional site foregrounds online appointment access and professional profiles with patient reviews. Doctoralia's Spanish specialist offering combines visibility with patient-management functions. MioDottore's Italian professional site similarly spans discovery, appointments and practice administration.
These overlaps help explain why the businesses belong in one analytical discussion. They do not justify copying a feature comparison from one market into another. A particular integration, payment option or clinical tool may be available only within a local package or require separate configuration.
When a supplier describes an international capability, ask for a demonstration in the version and language your team will actually use. The relevant evidence is a working local workflow and a written contractual scope.
The ecosystem contains more than directories
A directory helps a patient identify a clinician. Scheduling tools manage access to the practice. Communication, records and payments can extend the relationship further into everyday operations. Each additional function can create useful connections, but also a different degree of dependence.
MioDottore's current plan information, for example, lists named AI booking and clinical-reference components within specified offerings. This illustrates why a modern platform comparison should inspect the whole package rather than assume the business stops at a public profile.
The important distinction is functional. An administrative assistant, a clinical reference tool and a patient-review service need different evaluation criteria. They should not all inherit the same assessment simply because one supplier bundles them together.
Why ownership is commercially relevant
Group ownership can influence product investment, shared infrastructure and the way services are packaged. Those are reasons to ask better questions, not to assume a particular outcome. A larger group might offer useful integration and support, while the local contract still determines what the individual practice receives.
For a practice comparing alternatives, check whether seemingly separate products depend on the same supplier or group. Two differently branded services may not provide the degree of commercial diversification their names suggest.
Conversely, common ownership does not mean buying two products is automatically wasteful. They may address different needs. The correct test is whether their functions and costs overlap materially in your practice, and whether the arrangement remains useful when assessed as a whole.
Country coverage does not confer clinical eligibility
A doctor seeing that a group operates internationally should not infer that joining one platform allows clinical work in every market. Registration, licensing, indemnity, employer restrictions and the rules applying to remote care need separate assessment in the relevant jurisdictions.
The same caution applies to public qualifications and titles. A description suitable for one country may be misunderstood elsewhere. Confirm how the platform verifies professional identity and how the profile distinguishes language ability, training history and actual authority to practise.
For a clinician relocating, treat the new country as a fresh operational project. Establish the lawful practice model first, then choose a platform that supports it. International brand recognition is helpful context, not an alternative to local professional preparation.
Reputation may not be portable in the way you expect
Do not assume that reviews, ranking or profile history can be transferred between country brands. Ask what the company actually permits and how patients will see the resulting information. Any migration should preserve accuracy and avoid creating an impression that feedback relates to a different service or location.
A clinician can maintain a consistent professional identity through accurate qualifications, service descriptions and direct contact information. That does not require making unsupported claims about ratings or importing feedback into a new context without explanation.
This distinction matters commercially. A practice relying heavily on one profile should understand which parts of its online presence it can maintain independently if it moves, changes supplier or stops paying for a particular package.
Evaluate local demand rather than group scale
Group-wide audience and appointment figures can explain the size of the business, but they do not establish local demand for a specialty. A clinician needs evidence about appropriate enquiries in the location and appointment types they can actually serve.
Track the route from first discovery to a suitable completed consultation. Separate existing patients booking through the platform from people newly introduced by it. Ask what the provider's reports mean by a booking, a new patient and a conversion.
A large audience is commercially useful only when it connects with available, appropriate care. A full diary, an unsuitable service category or an inconvenient location can limit value regardless of the scale of the group behind the product.
Review data and exit arrangements at the local level
The privacy notice and service contract should identify the relevant organisations and processing arrangements. Shared ownership should not be treated as unrestricted permission for information to move between products or countries. Obtain appropriate advice where the structure is complex.
Ask how records, appointments and communications can be exported, which formats are available and what remains accessible after termination. Test an export before it becomes urgent. Clarify the position for a clinician leaving a group practice as well as for the practice changing supplier.
The wider iatroX article on platform dependence offers a useful commercial framework. Its questions about concentration and switching can be adapted internationally, while local legal requirements need their own review.
Compare the whole package without losing clinical focus
Create a short requirements document covering discovery, booking, communication, records, payments, support and any AI functions. Mark which elements are essential, which are useful and which would duplicate systems already working well.
For clinical learning or reference tools, assess the actual content, sources and jurisdiction rather than choosing solely on price or bundling. Resources such as iatroX's clinical guidance hub serve a different purpose from patient acquisition, even when commercial platforms now offer adjacent functionality.
Understanding Docplanner's ecosystem helps clinicians ask informed questions. The final decision, however, remains local and practical: which product supports the practice, on what terms, at what full cost and with what route to change later? Shared ownership is part of that assessment, not its conclusion.
FAQs
Are Doctoralia, MioDottore and jameda related?
Yes. Docplanner identifies these brands within its international group. They operate in different markets, so the relevant local product and contract should still be assessed separately.
Does a subscription in one country provide access to every Docplanner market?
Do not assume so. Check the actual agreement, product availability and professional eligibility. Group presence does not confer cross-border clinical licensing or universal package access.
Can a clinician transfer reviews between the different brands?
That should be confirmed directly under the applicable platform rules. Shared ownership does not establish automatic portability of reviews, rankings or profile history.